IA
ENZY

Icon Advisers’s Enzymotec Ltd ENZY Stock Holding History

Icon Advisers’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-31,417
Closed -$220K – 471
2016
Q3 		$220K Buy
31,417
+14,617
+87% +$117K 0.01% 413
2016
Q2 		$140K Hold
16,800
– – 0.01% 374
2016
Q1 		$152K Buy
+16,800
New +$146K 0.01% 332

Other funds holding ENZY

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Icon Advisers's ENZY Position: Q4 2016 in Review

Icon Advisers sold out of Enzymotec Ltd (ENZY) in Q4 2016, closing a stake of 31,417 shares — an estimated $220K sold.

Icon Advisers first reported a position in ENZY in Q1 2016 and held it in 3 quarters. The position peaked at $220K in Q3 2016. 32 funds tracked by Wall St. Rank hold ENZY as of Q4 2016.

  • Icon Advisers reported no remaining Enzymotec Ltd position as of Q4 2016 after selling out during the quarter.
  • Icon Advisers sold 31,417 Enzymotec Ltd shares in Q4 2016, an estimated $220K.
  • Icon Advisers first reported a position in Enzymotec Ltd in Q1 2016 and held it in 3 quarters.
  • Icon Advisers's Enzymotec Ltd position peaked at $220K in Q3 2016.
  • 32 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q4 2016.

Based on Icon Advisers's 13F filing for Q4 2016, filed 1 Feb 2017.